We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biodynamics Plc | LSE:OBD | London | Ordinary Share | GB00BD5H8572 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.29 | 3.30% | 9.09 | 8.70 | 9.48 | 8.94 | 8.70 | 8.80 | 308,828 | 16:35:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.34M | -10.83M | -0.0535 | -1.63 | 17.6M |
TIDMOBD
RNS Number : 5604R
Oxford BioDynamics PLC
30 June 2020
30 June 2020
Oxford BioDynamics Plc
( "OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Peter Pack, Non-Executive Chairman, has purchased 15,000 ordinary shares of 1 pence each ("Ordinary Shares") at an average price of 62.00p* per Ordinary Share.
Following this transaction, Peter Pack is interested in 15,000 Ordinary Shares, representing 0.02% of the Company's current issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities/person closely associated a) Name Peter Pack -------------------------- ----------------------------------------------- 2 Reason for the notification --------------------------------------------------------------------------- a) Position/status Non-Executive Chairman -------------------------- ----------------------------------------------- b) Initial notification/ Initial notification Amendment -------------------------- ----------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --------------------------------------------------------------------------- a) Name Oxford BioDynamics Plc -------------------------- ----------------------------------------------- b) LEI 2138005Y1TK258O5U928 -------------------------- ----------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --------------------------------------------------------------------------- a) Description of the Ordinary Shares of 1 pence each financial instrument, ISIN: GB00BD5H8572 type of instrument Identification code -------------------------- ----------------------------------------------- b) Nature of the transaction Acquisition of ordinary shares -------------------------- ----------------------------------------------- c) Price and volume Price(s) Volume(s) 0.6 2 1 5,000 ---------- -------------------------- ----------------------------------------------- d) Aggregated information Price Volume - Aggregated volume 0.6 2 1 5,000 - Price -------- -------------------------- ----------------------------------------------- e) Date of the transaction 29 June 2020 -------------------------- ----------------------------------------------- f) Place of the transaction Outside a trading venue (Börse Stuttgart) -------------------------- -----------------------------------------------
* average price calculated using average GBP/EUR exchange rate on the date of the transaction of 1EUR = GBP0.91383
For further details please contact:
Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO +44 (0)1865 518910 Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield John More +44 (0)20 7408 4090 FTI Consulting Financial Public Relations Adviser Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch(TM), offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch(TM) offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHFMMTTMTMJBJM
(END) Dow Jones Newswires
June 30, 2020 08:04 ET (12:04 GMT)
1 Year Oxford Biodynamics Chart |
1 Month Oxford Biodynamics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions